Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit

New York, NY — November 21, 2013 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company engaged in the development of novel drug candidates for the treatment of Alzheimer’s disease, CNS and oncology, today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate…